Find Docs

BioTech Navigator Investment Newsletter - 1 00 News (Page 3)

Wodocs >> Business : Biotechnology and Pharmaceuticals >> BioTech Navigator Investment Newsletter 1 00 News Page 3
BioTech Navigator Investment Newsletter - 1 00 News
3
BioTech Sage Report, January 2000
psoriasis.
What are some of the more
promising compounds
generated by biotechnology for
psoriasis?
Medical research scientists con-
tinue to search for genes that contrib-
ute to the inherited and other causes
of psoriasis. Scientists are also work-
ing to improve our understanding of
what happens in the body to trigger
this disease. In addition, much re-
search is focused on developing new
and better treatments. Some of these
experimental treatments, such as
agents directed at the specific types of
T cells involved, work to improve the
disease with less overall suppression
of the immune system. Whereas oth-
ers experimental therapies target cyto-
kines that are found in abundance in
psoriatic lesions. Each of the experi-
mental approaches has positives at-
tribute and will be evaluated below.

In earlier issues of BioTech Sage
Report (BSR), we discuss immuno-
modulatory proteins, which included
cytokines. For psoriasis, a number of
scientific studies have shown that in-
terleukin-8 (IL-8) may have a contrib-
uting role in the development of the
disease. IL-8, an important inflamma-
tory cytokine produced at sites of in-
flammation, attracts and activates
white blood cells that mediate the in-
flammation process. Clinical studies
have demonstrated significantly in-
creased levels of IL-8 in plasma or
other bodily fluids of patients with
certain inflammatory diseases, includ-
ing psoriasis, rheumatoid arthritis,
reperfusion injury and inflammatory
bowel disease. Antibodies to IL-8
have been shown to block immune
cell infiltration and the associated pa-
thology in animal models of several of
these diseases. Using their patented
XenoMouse technology, Abgenix has
generated ABX-IL8, a proprietary
fully human monoclonal antibody
that binds to IL-8 with high affinity.
Abgenix is currently evaluating
ABX-IL8 for possible use in the treat-
ment of psoriasis and rheumatoid ar-
thritis.

IL-8 should prove to be an effec-
tive target for treating psoriasis.
Concentrations of IL-8 are reported to
be elevated by a factor of 150 in pso-
riatic plaques when compared to nor-
mal tissue. Abgenix believes that IL-
8 may promote psoriasis by contribut-
ing to three distinct disease-
associated processes. First, IL-8 is
produced by a type of skin cell called
keratinocytes, and is a potent growth
factor for these skin cells. It may
therefore contribute to the abnormal
keratinocyte proliferation in psoriatic
plaques. Second, IL-8 attracts and
activates immune cells, which con-
tribute to the inflammation of the
psoriatic plaque. Finally, IL-8 pro-
motes angiogenesis, which augments
the blood supply necessary for growth
of the psoriatic plaque.

Abgenix has completed a Phase I
dose-escalating human clinical trial
examining the safety of administering
a single intravenous infusion of five
different doses of ABX-IL8 to pa-
tients with moderate to severe psoria-
sis. From these studies, Abgenix
found that there were no serious or
unexpected drug-related adverse
events. Abgenix is currently awaiting
the results of a multi-center, multi-
dose, dose-escalating study in moder-
ate to severe psoriasis patients. BSR
is extremely optimistic that ABX-IL8
will do well and make it to market, as
the principle behind the therapy is
similar to Immunex and Centocor's
approach to treat rheumatoid arthri-
tis. However, we believe the technol-
ogy is superior, as the antibody is al-
ready humanized and will not induce
an anti-antibody response in patients
or be subjected to the lengthy altera-
tions associated with humanizing it
for therapeutic utility.
An alternative approach is to at-
tack the cell types that are involved in
the autoimmune response. Biogen
has focused their efforts on it's in-
flammation programs for developing
drugs to inhibit specific cellular inter-
actions critical to the inflammation
process. Central to inflammation is
the activation of T-cells. One of the
cellular pathways, which is important
for the activation of T-cells is the
LFA-3/CD2 pathway. Biogen has
developed AMEVIVE (LFA3TIP) a
recombinantly engineered protein de-
signed to modulate immune responses
by binding to the CD2 receptor. Bio-
gen is evaluating AMEVIVE as a
treatment for certain autoimmune dis-
eases, including psoriasis. In 1998,
Biogen completed evaluation of the
results of two Phase 2a safety studies
of AMEVIVE, and commenced a
Phase 2b study of the safety and effi-
cacy of AMEVIVE compared to a pla-
cebo as a systemic therapy in patients
with moderate and severe psoriasis.
Earlier this month (December), Bio-
gen announced the results of this
Phase II study, which involved 229
patients at 22 sites in the U.S. who
were treated with AMEVIVE or pla-
cebo by intravenous bolus injection
weekly for 12 weeks, followed by a
12-week observation period. The pri-
mary study objective was to determine
the relationship of clinical response to
the dose of AMEVIVE when adminis-
tered once a week for a total of up to
12 doses. The results showed that
AMEVIVE was well tolerated with a
favorable safety profile and provided
significant therapeutic effect. No in-
crease in infection rate or evidence of
cytokine-release or capillary-leak syn-
dromes was observed in AMEVIVE-
treated patients. Results indicate that
AMEVIVE cleared psoriasis rapidly
and to a significant degree. In particu-
lar, in patients who received either of
the two higher doses of AMEVIVE

<< Previous       1 2 3 4 5 6 7 8 9 10 11 12 13 14 15       Next >>



Other Documents:
1 04 News Color Blank, Handpainted Catalog F, Oil Lamps Unlimited E Brochure, Order Form Retailb, Order Form specialpricing, jobapplication, SFmenu 2006, jobapplication, reheating, Holiday menu 2005 2, Signe's Holiday Menu, Holiday menu 2005 2, 22 aug 2001, 22 sept 2003, 31 Aug 2002, Eagles 121605, Rose Bowl Fan 2 Fan 120505, Rose Bowl Preferred 111405, C 15 Entry Form pg 2 ( ENG), C 15 Entry Form pg 2 ( FR), C17 entryform, C18 Community serv, Contessa 15 Finalists, Contessa 15 Semi Finalists, contessa 14 finalists, c16 eng entryform, c16 fr entryform, b.loreal.comp, checklist, Beautynet ad info, CIABC MK, Elevate Media Kit, Salon Ad Specs, hair removal options, Amst Menu Guide 07 02, Amst Menu Guide 07 04, Amst Menu Guide 07 05, Amst Menu Guide 07 06, Amst Menu Guide 07 07, Amst Menu Guide 07 08, Amst Menu Guide 07 09, Amst Menu Guide 07 10, Amst Menu Guide 07 11, Amst Menu Guide 07 13, Amst Menu Guide 07 14, Amst Menu Guide 07 19, Amst Menu Guide 07 24, Amst Menu Guide 07 25, Amst Menu Guide 07 26, Amst Menu Guide 07 29,


WODocs | |
All rights reserved. wodocs.comę 2009
WODocs


New Docs

Documents Category:
Arts (Design, Movies, Music, Radio, Television)
Automotive (Cars, Marine, Motorcycle, ATV, Snowmobiles)
Business (Biotechnology and Pharmaceuticals, Chemicals, Construction and Maintenance, Materials, Real Estate, Services)
Electronics (Computers, Motion Control, Power Supply)
Games (Board, Family, Party, Card, Construction, RC Toys)
Health (Animalm, Beauty, Healthcare, Medicine, Pharmacy, Surgery, Weight Loss)
Home (Accessories, Cooking, Decor and Design, Electrical, Family, Pets)
News (Newspapers, Sports, Television)
Recreation (Collecting, Hiking, Scouting, Survival, Travel)
Reference (Education, Libraries and Archives, Museums)
Science (Agriculture, Astronomy, Biology, Chemistry)
Shopping (Antiques and Collectibles, Clothing, Flowers, Food, Home and Garden)
Sports (Bicycle, Snowboard, Skiing, Other)